Wdowiak Paulina, Matysiak Joanna, Kuszta Piotr, Czarnek Katarzyna, Niezabitowska Ewa, Baj Tomasz
Department of Human Anatomy, Medical University of Lublin, Lublin, Poland.
Department of Chemistry, Faculty of Food Science and Biotechnology, University of Life Sciences in Lublin, Lublin, Poland.
Front Chem. 2021 Nov 3;9:765552. doi: 10.3389/fchem.2021.765552. eCollection 2021.
Cancer diseases remain major health problems in the world despite significant developments in diagnostic methods and medications. Many of the conventional therapies, however, have limitations due to multidrug resistance or severe side effects. Bladder cancer is a complex disorder, and can be classified according to its diverse genetic backgrounds and clinical features. A very promising direction in bladder cancer treatment is targeted therapy directed at specific molecular pathways. Derivatives of quinazolines constitute a large group of chemicals with a wide range of biological properties, and many quinazoline derivatives are approved for antitumor clinical use, e.g.,: erlotinib, gefitinib, afatinib, lapatinib, and vandetanib. The character of these depends mostly on the properties of the substituents and their presence and position on one of the cyclic compounds. Today, new quinazoline-based compounds are being designed and synthesized as potential drugs of anticancer potency against bladder cancers.
尽管诊断方法和药物有了重大进展，但癌症疾病仍然是世界上主要的健康问题。然而，许多传统疗法由于多药耐药性或严重的副作用而存在局限性。膀胱癌是一种复杂的疾病，可以根据其不同的遗传背景和临床特征进行分类。膀胱癌治疗中一个非常有前景的方向是针对特定分子途径的靶向治疗。喹唑啉衍生物构成了一大类具有广泛生物学特性的化学物质，许多喹唑啉衍生物已被批准用于抗肿瘤临床应用，例如：厄洛替尼、吉非替尼、阿法替尼、拉帕替尼和凡德他尼。这些药物的特性主要取决于取代基的性质及其在其中一种环状化合物上的存在和位置。如今，新型喹唑啉基化合物正在被设计和合成，作为对抗膀胱癌具有抗癌效力的潜在药物。
